- Home
- RLYB vs VIVO Comparison
RLYB vs VIVO Comparison
Compare RLYB & VIVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLYB | VIVO |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Power Generation |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.9M | 37.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RLYB | VIVO |
|---|---|---|
| Price | $13.89 | $2.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 60.9K | ★ 865.1K |
| Earning Date | 05-11-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $858,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.00 | N/A |
| 52 Week Low | $0.27 | $1.97 |
| 52 Week High | $11.49 | $4.27 |
Technical Indicators
Market Signals| Indicator | RLYB | VIVO |
|---|---|---|
| Relative Strength Index (RSI) | 89.64 | 51.83 |
| Support Level | $0.54 | $1.97 |
| Resistance Level | N/A | $3.50 |
| Average True Range (ATR) | 0.43 | 0.44 |
| MACD | 0.36 | -0.01 |
| Stochastic Oscillator | 88.65 | 24.14 |
Price Performance
Historical ComparisonAbout RLYB Rallybio Corporation
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.